CVRdatabase
Menu

ResoTher Pharma A/S

Public limited companyCVR 37852406HolteActive

ResoTher Pharma A/S is a public limited company, based in Holte, active in research and experimental development on natural sciences and engineering, founded in 2016. The company made a loss in both 2024 and 2025, most recently DKK 9.3m. 7 people are registered in the company's management and ownership.

Follow
PDF reportCompare

Key figures · financial year 2025

Net profit−DKK 9.3m+7.8% vs. 2024
EquityDKK 12.1m+0.1% vs. 2024
Employees4latest month from CVR

What has changed

calculated from recorded figures and dates

Financials: 2025 against 2024

  • The loss got smaller: from DKK 10.1m to DKK 9.3m (2024 → 2025).

Employees

  • 1 more employees than a year earlier: 4 (07/2026) against 3 (07/2025).

Management and owners, last 24 months

  • New in management: Thomas Engelbrecht Nordkild Jonassen (board member, 15/12/2025), Rebecca Anne Morison (chair of the board, 15/12/2025) and Michael Østerlund Madsen (board member, 29/06/2026) (+2).
  • Stepped down: Kirsten Aarup Drejer (chair of the board, 23/06/2025), Thomas Feldthus (board member, 23/06/2025) and Thomas Engelbrecht Nordkild Jonassen (chair of the board, 14/12/2025) (+1).

Registrations, last 24 months

  • 20/05/2026: Share capital changed from 571,460 DKK to 608,678 DKK
  • 21/10/2025: Share capital changed from 542,894 DKK to 571,460 DKK
  • 01/01/2025: Industry changed to Research and experimental development on natural sciences and engineering (721000)

Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.

Financial statements

Financial years 2020–2025 · amounts in DKK thousand

Equity and net profit

−DKK 30m−DKK 20m−DKK 10mDKK 0DKK 10mDKK 20mDKK 30mDKK 40m202020212022202320242025
EquityNet profit
Financial figures for ResoTher Pharma A/S
202020212022202320242025Change
Revenuenot statednot statednot statednot statednot statednot stated–
Operating profit (EBIT)−7,084−12,717−32,409−19,878−12,825−12,134+5.4%
Profit before tax−7,581−13,606−32,718−19,891−12,837−12,204+4.9%
Net profit−5,196−11,678−27,218−17,498−10,071−9,290+7.8%
Total assets4,53541,4061821,76114,84716,387+10.4%
Equity−56038,63112,17420,76012,12212,132+0.1%
Liabilities–2,7755,6321,0012,7254,255+56.1%
Cash and cash equivalents1,29023,61111,77717,46611,0629,446−14.6%

Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2020, 2021, 2022, 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.

Download the figures as CSV · free with an account, amounts in whole DKK

−DKK 30m−DKK 25m−DKK 20m−DKK 15m−DKK 10m−DKK 5mDKK 0202020212022202320242025
Net profitMedian, the industry (431 companies)

Signals from the financial statements

calculated from the 2025 figures

  • Loss for 6 years in a row

    Net result has been negative in 2020–2025.

    How is this calculated?

    Net result is negative in the two or more latest annual reports in a row.

The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.

Annual reports

6 financial years
Annual reports for ResoTher Pharma A/S
Financial yearPeriodPublishedFigures forDocuments
202501/01/2025 – 31/12/202507/07/2026The companyPDF not statedXBRL
202401/01/2024 – 31/12/202429/06/2025The companyPDFXBRL
202301/01/2023 – 31/12/202328/06/2024The companyPDF not statedXBRL
202201/01/2022 – 31/12/202205/07/2023The companyPDF not statedXBRL
202101/01/2021 – 31/12/202124/06/2022The companyPDF not statedXBRL
202001/01/2020 – 31/12/202016/06/2021The companyPDF not statedXBRL

The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.

Employees

monthly figures from CVR
024681008/2309/2310/2311/2312/2301/2402/2403/2404/2405/2406/2407/2408/2409/2410/2411/2412/2401/2502/2503/2504/2505/2506/2507/2508/2509/2510/2511/2512/2501/2602/2603/2604/2605/2606/2607/26
Employees

Position in the industry

431 companies in the database

Comparison with the other companies in research and experimental development on natural sciences and engineering based on the latest financial year.

EquityDKK 12.1mNo. 131 of 431
Better than 70% of the companies in the industry
Number of employees4No. 224 of 431
Better than 48% of the companies in the industry

Industry median: gross profit DKK 616k, net profit −DKK 892k, equity DKK 2m, 5 employees.

DKK 100kDKK 2.5mDKK 63.4mDKK 1.6bnDKK 13.7bn
Distribution of gross profit for 250 companies in the industry (latest financial year, logarithmic scale).

Compared with similar companies

size, age and company form
Rank among similar companies
GroupGross profitEquity
Companies with fewer than 20 employees69,967 companies in the comparisonnot stated
No. 7,978of 69,964
Better than 89%
Same industry and fewer than 20 employees329 companies in the comparisonnot stated
No. 57of 329
Better than 83%
Companies that are between 5 and 14 years old33,688 companies in the comparisonnot stated
No. 3,277of 33,687
Better than 90%
All companies of type A/S18,025 companies in the comparisonnot stated
No. 7,993of 18,024
Better than 56%

The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.

Compare with the industry

Research and experimental development on natural sciences and engineering
Gross profit
  1. ResoTher Pharma A/S–
  2. Carlsberg A/SDKK 40.2bn
  3. Zealand Pharma A/SDKK 9.2bn
Net profit
  1. ResoTher Pharma A/S−DKK 9.3m
  2. Carlsberg A/SDKK 7bn
  3. Zealand Pharma A/SDKK 6.5bn
Equity
  1. ResoTher Pharma A/SDKK 12.1m
  2. Carlsberg A/SDKK 30.7bn
  3. Zealand Pharma A/SDKK 14.8bn
Employees
  1. ResoTher Pharma A/S4
  2. Carlsberg A/S107
  3. Zealand Pharma A/S569

Latest financial year per company. Choose up to three companies from the largest in the industry.

Owners and group

from the Public Ownership Register
Owners
  • Quantass ApS5%
  • TJ Biotech Holding ApS5%
ResoTher Pharma A/S

Management

8 active registrations

Executive management

Executive management at ResoTher Pharma A/S
NameRoleAppointed
Anders KronborgCEO01/02/2023

Board of directors

Board of directors at ResoTher Pharma A/S
NameRoleAppointed
Henrik StageBoard member23/11/2017
Jeppe Øvli ØvlesenBoard member11/07/2018
Sven Martin JacobsonBoard member31/05/2021
Roderick John FlowerBoard member28/06/2023
Thomas Engelbrecht Nordkild JonassenBoard member15/12/2025
Rebecca Anne MorisonChair of the board15/12/2025
Michael Østerlund MadsenBoard member29/06/2026
Founders
TJ Biotech Holding ApS, Quantass ApS
Former management (12)
Former management at ResoTher Pharma A/S
NameRoleAppointedResigned
Jeppe Øvli ØvlesenChair of the board04/07/201610/07/2018
Thomas Engelbrecht Nordkild JonassenCEO04/07/201623/11/2017
Thomas Engelbrecht Nordkild JonassenBoard member04/07/201623/11/2017
Lone Merete VengBoard member19/04/201723/11/2017
Mette MunchBoard member23/11/201729/05/2019
Lone Merete VengCEO23/11/201731/01/2023
Kirsten Aarup DrejerBoard member30/04/201810/07/2018
Kirsten Aarup DrejerChair of the board11/07/201823/06/2025
Lars Henning StigelBoard member29/05/201931/05/2021
Thomas FeldthusBoard member31/05/202123/06/2025
Thomas Engelbrecht Nordkild JonassenChair of the board23/06/202514/12/2025
Rebecca Anne MorisonBoard member23/09/202514/12/2025

Signing rule: Selskabet tegnes af en direktør og et bestyrelsesmedlem i forening, eller af den samlede bestyrelse.

Address and production units

1 active production units

Dronninggårds Alle 136
2840 Holte

Rudersdal Municipality · Postcode 2840

Other companies at the address (2)

Production units
Production unitAddressEmployeesP number
ResoTher Pharma A/SDronninggårds Alle 136, 2840 Holte41021570172

Purpose

Selskabet har til formål at gennemføre forskning i og udvikling af peptidbaserede lægemidler rettet mod inflammation, forprogrammeret celledød, cancer samt koagulerings- og blodlegmesygdomme, med særlig fokus på Annexin A1-deriverede peptider; at foretage investeringer i interesser, som gennemfører tilsvarende aktiviteter, herunder i immaterielle rettigheder knyttet til sådanne; og at gennemføre med lægemiddeludvikling relaterede aktiviteter.

The purpose is quoted from the register in Danish.

Changes year by year

98 registered events
20263 changesaccounts 1 · management 1 · capital 1
  • Annual report for 2025 published
  • Michael Østerlund Madsen appointed board member
  • Share capital changed from 571,460 DKK to 608,678 DKK
202511 changesmanagement 8 · capital 1 · accounts 1 · industry 1
  • Rebecca Anne Morison appointed chair of the board
  • Thomas Engelbrecht Nordkild Jonassen appointed board member
  • Rebecca Anne Morison stepped down as board member
  • Thomas Engelbrecht Nordkild Jonassen stepped down as chair of the board
  • Share capital changed from 542,894 DKK to 571,460 DKK
  • Rebecca Anne Morison appointed board member
  • Annual report for 2024 published
  • Thomas Engelbrecht Nordkild Jonassen appointed chair of the board
  • Thomas Feldthus stepped down as board member
  • Kirsten Aarup Drejer stepped down as chair of the board
  • Industry changed to Research and experimental development on natural sciences and engineering (721000)
20241 changeaccounts 1
  • Annual report for 2023 published
20236 changescapital 2 · accounts 1 · management 3
  • Share capital changed from 537,630 DKK to 542,894 DKK
  • Annual report for 2022 published
  • Share capital changed from 459,736 DKK to 537,630 DKK
  • Roderick John Flower appointed board member
  • Anders Kronborg appointed ceo
  • Lone Merete Veng stepped down as ceo
20223 changesaccounts 1 · name 1 · capital 1
  • Annual report for 2021 published
  • Name changed from ResoTher Pharma ApS to ResoTher Pharma A/S
  • Share capital changed from 229,868 DKK to 459,736 DKK
202119 changescapital 3 · ownership 12 · accounts 1 · management 3
  • Share capital changed from 201,268 DKK to 229,868 DKK
  • Quantass ApS registered as owner (5%)
  • TJ Biotech Holding ApS registered as owner (5%)
  • TJ Biotech Holding ApS is no longer registered as owner
  • Quantass ApS is no longer registered as owner
  • Annual report for 2020 published
  • Sven Martin Jacobson appointed board member
  • Thomas Feldthus appointed board member
  • Lars Henning Stigel stepped down as board member
  • Share capital changed from 192,468 DKK to 201,268 DKK
  • Uddannelses- og Forskningsstyrelsen is no longer registered as owner
  • Share capital changed from 112,923 DKK to 192,468 DKK
  • TJ Biotech Holding ApS registered as owner (10%)
  • Quantass ApS registered as owner (10%)
  • Uddannelses- og Forskningsstyrelsen registered as owner (5%)
  • Pinnacle Holding ApS is no longer registered as owner
  • Quantass ApS is no longer registered as owner
  • TJ Biotech Holding ApS is no longer registered as owner
  • Uddannelses- og Forskningsstyrelsen is no longer registered as owner
20209 changesownership 8 · capital 1
  • Quantass ApS registered as owner (15%)
  • TJ Biotech Holding ApS registered as owner (15%)
  • QUANTASS ApS is no longer registered as owner
  • TJ BIOTECH HOLDING ApS is no longer registered as owner
  • Share capital changed from 103,121 DKK to 112,923 DKK
  • QUANTASS ApS registered as owner (15%)
  • TJ BIOTECH HOLDING ApS registered as owner (15%)
  • TJ BIOTECH HOLDING ApS is no longer registered as owner
  • QUANTASS ApS is no longer registered as owner
201911 changescapital 1 · ownership 8 · management 2
  • Share capital changed from 81,712 DKK to 103,121 DKK
  • Uddannelses- og Forskningsstyrelsen registered as owner (10%)
  • TJ BIOTECH HOLDING ApS registered as owner (20%)
  • QUANTASS ApS registered as owner (20%)
  • Pinnacle Holding ApS registered as owner (5%)
  • Pinnacle Holding ApS is no longer registered as owner
  • QUANTASS ApS is no longer registered as owner
  • Uddannelses- og Forskningsstyrelsen is no longer registered as owner
  • TJ BIOTECH HOLDING ApS is no longer registered as owner
  • Lars Henning Stigel appointed board member
  • Mette Munch stepped down as board member
20185 changesmanagement 5
  • Kirsten Aarup Drejer appointed chair of the board
  • Jeppe Øvli Øvlesen appointed board member
  • Kirsten Aarup Drejer stepped down as board member
  • Jeppe Øvli Øvlesen stepped down as chair of the board
  • Kirsten Aarup Drejer appointed board member
201724 changescapital 1 · management 7 · ownership 16
  • Share capital changed from 50,000 DKK to 81,712 DKK
  • Lone Merete Veng appointed ceo
  • Mette Munch appointed board member
  • Henrik Stage appointed board member
  • Lone Merete Veng stepped down as board member
  • Thomas Engelbrecht Nordkild Jonassen stepped down as board member
  • Thomas Engelbrecht Nordkild Jonassen stepped down as ceo
  • Pinnacle Holding ApS registered as owner (10%)
  • QUANTASS ApS registered as owner (25%)
  • Uddannelses- og Forskningsstyrelsen registered as owner (15%)
  • TJ BIOTECH HOLDING ApS registered as owner (25%)
  • Mauro Antonia Italo Perretti is no longer registered as owner
  • Pinnacle Holding ApS is no longer registered as owner
  • QUANTASS ApS is no longer registered as owner
  • TJ BIOTECH HOLDING ApS is no longer registered as owner
  • Mauro Antonia Italo Perretti registered as owner (5%)
  • Lone Merete Veng appointed board member
  • Lone Merete Veng registered as owner (15%)
  • Lone Merete Veng is no longer registered as owner
  • Pinnacle Holding ApS registered as owner (15%)
  • QUANTASS ApS registered as owner (33.33%)
  • TJ BIOTECH HOLDING ApS registered as owner (33.33%)
  • TJ BIOTECH HOLDING ApS is no longer registered as owner
  • QUANTASS ApS is no longer registered as owner
20166 changesfounded 1 · management 3 · ownership 2
  • Registered as ResoTher Pharma ApS
  • Jeppe Øvli Øvlesen appointed chair of the board
  • Thomas Engelbrecht Nordkild Jonassen appointed board member
  • Thomas Engelbrecht Nordkild Jonassen appointed ceo
  • TJ BIOTECH HOLDING ApS registered as owner (50%)
  • QUANTASS ApS registered as owner (50%)

Related companies

Same industry in Rudersdal

See all →

Same people in management

Largest in the industry

See all →

Source and updates

The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026. The company is protected against advertising; contact details are not shown, and the data must not be used for marketing.

View in CVRReport a correction